Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. - Test2 - elhamkhani - TriplyDB

Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course.

Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course.

http://www.wikidata.org/entity/Q34950897

about

The perils of PCR: can we accurately 'correct' antimalarial trials?Cerebrospinal fluid analysis in the HIV infection and compartmentalization of HIV in the central nervous system Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia Alarmins and central nervous system inflammation in HIV-associated neurological disorders.HIV subtype is not associated with dementia among individuals with moderate and advanced immunosuppression in Kampala, Uganda.Daily sampling of an HIV-1 patient with slowly progressing disease displays persistence of multiple env subpopulations consistent with neutrality HIV-1 replication in the central nervous system occurs in two distinct cell types.Emergence of CD4 independence envelopes and astrocyte infection in R5 simian-human immunodeficiency virus model of encephalitis.Central nervous system compartmentalization of HIV-1 subtype C variants early and late in infection in young children Neurologic complications of HIV disease and their treatment.Translational challenges in targeting latent HIV infection and the CNS reservoir problem.Controversies in HIV-associated neurocognitive disorders Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study HIV-1 target cells in the CNS.Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection.Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy Viral determinants of HIV-1 macrophage tropism.Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS.Longitudinal Analysis of Cerebrospinal Fluid and Plasma HIV-1 Envelope Sequences Isolated From a Single Donor with HIV Asymptomatic Neurocognitive Impairment.The cerebrospinal fluid proteome in HIV infection: change associated with disease severity HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment.Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders.Early Antiretroviral Therapy Is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations Well-mixed plasma and tissue viral populations in RT-SHIV-infected macaques implies a lack of viral replication in the tissues during antiretroviral therapy.Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment.Interplay between Wnt/β-catenin signaling and HIV: virologic and biologic consequences in the CNS.HIV-1 pathogenesis: the virus.Envelope gene evolution and HIV-1 neuropathogenesis.The HIV-1 env protein: a coat of many colors.Tissue reservoirs of HIV Tissue-specific HIV-1 infection: why it matters.HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads.Different levels of HIV DNA copy numbers in cerebrospinal fluid cellular subsets.Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy.Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration?Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract.An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy.Neurocognitive impact of antiretroviral treatment: thinking long-term.CSF penetration by antiretroviral drugs.Understanding HIV compartments and reservoirs.

P2860

Q24615919-98B7FE12-4985-4964-929B-D3D1347E77E0 Q26801033-24C622C8-AE3F-4680-A814-143593F8B2EF Q28475360-4E9BFD02-E44B-4E1D-8D9F-5D8C7A300F4C Q30241037-463342F6-48FB-4CBA-B41F-DC63C9E84416 Q33624877-F715959A-D513-482A-945B-C04348F8EF9D Q33988303-CAC56AD5-3FEE-4AF2-A059-A4B75BB7EF97 Q34050421-0195F711-4A4D-40E2-AA42-CF19D986D1BF Q34057907-5B4480E5-7313-45B9-A6C5-76AECBF712DF Q34539781-2A0F8A1B-94B6-4DD4-8044-9B785DB4E4E8 Q34730716-A34E8341-68FF-40FA-B689-9A45729C4A9D Q35009744-F1992965-E594-432E-AAFE-0EB41966764A Q35037015-05C14765-B145-4365-B0F4-18DA90E4D497 Q35052651-764200E3-1DEF-41F4-A4C4-E3E8809F409C Q35196509-EEABA1D4-82F7-46FD-937C-8A4EEDD1D583 Q35219829-F1F8917C-145B-4EFC-90C6-FDEDD9741BAC Q35532868-B54079D0-07F4-4809-8BF9-D7518AA77B5A Q35593158-C1FB9161-7ACA-4E43-9B2C-30A3E880B765 Q35606068-DF6CF80E-9894-4B09-9DCD-CA169C3FE4CB Q35838394-F12A3D6D-B73B-4993-BC82-0B45FC2BBE59 Q35965332-294010A4-1111-4E94-BDBC-D067746286E6 Q36009246-BEAFB1E4-2D91-4E3E-8FF3-39385A3E4743 Q36204440-6E96C642-4E9F-48A8-81C0-B0E03298376A Q36238501-805562F3-1894-40C7-B0FA-6A84C65649B9 Q36273849-7F46A55C-79D1-4448-B0C5-813B3B7888CD Q36303531-D3A8F14A-A595-47B7-B16C-1A1B615A6EFC Q36456823-3375DCD6-ECAE-4F72-B59B-8CBEACEDA70B Q36526530-45758DDA-637D-41F8-9290-F4F2DFEA5E46 Q36847475-196166B8-F39F-4881-B95B-34C2C08CE4EA Q36856091-3EA1BE14-D009-42B1-BA94-CAA6F2457A26 Q37055454-54CCB7AA-BC28-4C1B-B266-5B9067F4AA62 Q37089202-B4345B1D-44A9-488A-8C2D-D1BD508DAF4E Q37300347-B22CA165-F924-4CE5-AF76-BB421CBAD516 Q37352656-C7048750-6320-4D21-8848-EF871E3E4A1F Q37354047-F5341C61-7163-4B56-A1F1-60C2CE98633A Q37362071-1387264D-D215-4997-8470-F34DF5965A32 Q37643618-9663EADA-5431-4891-9113-7706D672C8FB Q37719759-481BC1A1-01A0-42D8-A428-6C8306173E32 Q37916327-D28B4540-896A-472A-9DED-68B0023FE884 Q38060571-AA786EF5-6042-446B-8A6A-DBFD433B1DF7 Q38204313-4ACACF7C-C417-42A5-BEBE-80C84596769C

P2860

Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course.

http://www.wikidata.org/entity/Q34950897

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Cross-sectional characterizati ...... over the full disease course.

@ast

Cross-sectional characterizati ...... over the full disease course.

@en

Cross-sectional characterizati ...... over the full disease course.

@nl

type

label

Cross-sectional characterizati ...... over the full disease course.

@ast

Cross-sectional characterizati ...... over the full disease course.

@en

Cross-sectional characterizati ...... over the full disease course.

@nl

prefLabel

Cross-sectional characterizati ...... over the full disease course.

@ast

Cross-sectional characterizati ...... over the full disease course.

@en

Cross-sectional characterizati ...... over the full disease course.

@nl

P1433

Q34950897-958CFEB7-FB9B-4685-9D25-AEC21A85625F

P1476

Q34950897-9FD9723C-DBA8-48F5-B0F5-506C7189DC79

P2093

Q34950897-28581531-1E29-464C-95E9-37E3315842A3

Q34950897-30D59BF5-C175-46FD-AFEA-0BAAA8D749AE

Q34950897-3B098254-34D6-43B2-877C-7B6A395DFBF8

Q34950897-4E70DFF5-4E93-4BFD-B009-CF0691F5A117

Q34950897-6A8DE176-9999-4D3E-A5BA-AF69CE4FCE83

Q34950897-7CC2A256-0F38-4FA7-AA80-287C749198AB

Q34950897-C932F868-2494-4F72-83E6-8127873FB5EB

Q34950897-CCF87A82-58D9-4B60-8C14-A648A4A30684

P2860

Q34950897-00C245BE-71A2-49E7-AF7B-59B760ADAF7E

Q34950897-0444AA35-1EF2-467B-AE18-D839AA88DEBF

Q34950897-07D6C293-02E5-46A2-989E-B4785FCFA8BF

Q34950897-1E5F9CAC-EE7F-497A-8857-C87982788219

Q34950897-2A032E97-D8C5-4D2A-A407-8A2585F57531

Q34950897-2E84B1BC-DA04-4B25-AC4F-30625A660943

Q34950897-36A23AF8-BAEB-4105-B644-AEA8D9F6E7C6

Q34950897-41538852-C4C4-422C-A7AE-E289BB2EE3D6

Q34950897-47B1996D-7715-4F76-872A-4D7A406E449C

Q34950897-4B52CA6F-0481-4045-99CE-981394BBA2D2

P304

Q34950897-4221C05A-65AD-4481-9F74-1C65B698B174

P31

Q34950897-867FDD1E-9448-4DCF-A909-A935B45E2962

P356

Q34950897-81D4A371-406B-4742-A0DE-FDE3E77859CE

P407

Q34950897-A3F6AC58-7BD1-4E28-B2F5-FAE77D5954AE

P433

Q34950897-622E0B60-33A4-4FF5-B28F-AEDA3D8FBEDB

P478

Q34950897-519F05BE-429E-46CD-890E-D3F4E618CBF1

P50

Q34950897-0C0850C5-962D-4DF7-8B67-6E5A9391A43C

Q34950897-94D5FF26-5DBC-4CEE-B1E7-3C99DF4BCD56

Q34950897-9D7A869D-8CE4-4323-8704-DC5C5EC94F25

Q34950897-B0092AE9-3D7F-44EE-89B8-2FE3637CB338

Q34950897-FDD7EAD5-BE1D-416B-9FB5-54FA4C9A9C50

P577

Q34950897-43CB1B4E-B437-45DA-821F-406DE5EB8E3E

P5875

Q34950897-8D9B8D61-6C13-46B3-96FC-6C8BA532C31C

P698

Q34950897-D4FACAAF-9AB6-4928-A575-C9D8873B1972

P921

Q34950897-7E5372E7-5019-4638-B7D1-B969D422B327

P932

Q34950897-C364F861-B6BA-4EE6-B44B-B76616234533

P356

QAD.0B013E3283299129

P1433

P1476

Cross-sectional characterizati ...... over the full disease course.

@en

P2093

Cassandra B Jabara

http://www.w3.org/2001/XMLSchema#string

Colin Hall

http://www.w3.org/2001/XMLSchema#string

Dominic T Moore

http://www.w3.org/2001/XMLSchema#string

Gretja Schnell

http://www.w3.org/2001/XMLSchema#string

Kevin Robertson

http://www.w3.org/2001/XMLSchema#string

Kimberly Ritola

http://www.w3.org/2001/XMLSchema#string

Patrick R Harrington

http://www.w3.org/2001/XMLSchema#string

Richard W Price

http://www.w3.org/2001/XMLSchema#string

P2860

MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) Software Version 4.0

The neuropathogenesis of AIDS

Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.

Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection

Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells.

Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

Antiretroviral treatment of central nervous system HIV-1 infection: a review.

Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection

The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy.

P304

907-915

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E3283299129

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Christina L Burch

Ronald Swanstrom

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24401314

http://www.w3.org/2001/XMLSchema#string

P698

19414991

http://www.w3.org/2001/XMLSchema#string

P921

cerebrospinal fluid

P932

3089803

http://www.w3.org/2001/XMLSchema#string